Page URL:

Safer prenatal test for Down's syndrome launched in US

24 October 2011
Appeared in BioNews 630

A new prenatal test that can detect Down's syndrome by using a sample of the mother's blood was launched in twenty US cities last Monday.

MaterniT21, developed by the San Diego-based biotechnology company Sequenom, analyses fetal DNA in the mother's blood as early as ten weeks into the pregnancy. The test reveals whether the fetus has three copies of chromosome 21 instead of the usual two – a genetic chromosomal anomaly known as trisomy 21 and the most common cause of Down's syndrome.

The test could potentially eliminate the need for riskier invasive procedures, such as amniocentesis and CVS. Invasive techniques require samples of either a small amount of fluid that surrounds the fetus or placenta, and carry a slight risk of miscarriage.

Dr Harry Hixson, Sequenom's chief executive officer (CEO), said: 'We believe that the MaterniT21 [test] will provide physicians and their patients with critical new information to help them make better informed decisions about the patients' healthcare and pregnancies'.

A study, sponsored by Sequenom, published the results of a trial of this new test in the journal Genetics in Medicine. Using blood samples from pregnant women, the test identified 209 of the 212 Down's syndrome cases, a rate of 98.6 percent. It incorrectly characterised three of 1,471 normal fetuses as having the disorder, earning a false-positive rate of 0.2 percent. The existing tests, such as amniocentesis and CVS, have a false-positive rate of up to five percent.

'It's better than anything by far that we've ever seen in testing for Down's syndrome non-invasively', said Jacob Canick, professor of pathology at Brown University and the senior author of the study.

MaterniT21 would be ordered by doctors, not directly by consumers, and the analysis would occur in Sequenom's laboratories. The test is expected to cost around $1,900, about the same as an amniocentesis. However, the company alleged that 'the out-of-pocket cost of the test for insured patients will be no more than $235', assuming that the insurers will pay the rest. It is not yet clear how willing insurers will be to cover this test, nor has it yet been approved by the US Food and Drug Administration.

Some experts have also raised concerns that the safer test could lead to more screening and more terminated pregnancies. However, although Sequenom 'hopes the test would be used by women who choose not to undergo invasive tests because of the risk of miscarriage', the company mentioned that women who test positive would still be advised to undergo the more definitive invasive tests before terminating a pregnancy.

Another company, Verinata Health, is expected to launch a similar product in the first quarter 2012. Gene Security Network, which is currently testing its prenatal diagnostic test to detect chromosomal anomalies, hopes to have a test ready later in 2012.

Sequenom was also involved in introducing a prenatal Down's syndrome test back in 2009. However, the company faced a scandal related to mishandling the key clinical data, which led to the removal of its top management, including the former CEO and research chief. The episode was followed by legal and regulatory probes into the matter.
A Less Risky Down Syndrome Test Is Developed
New York Times |  17 October 2011
Company Launches Safer Test for Down Syndrome
Fox News |  18 October 2011
DNA sequencing of maternal plasma to detect Down
Genetics in Medicine |  25 January 2022
Prenatal blood test for Down syndrome available
LA Times |  19 October 2011
Safer Down Syndrome Test Hits Market Monday
ABC News |  18 October 2011
Sequenom Center for Molecular Medicine Announces Launch of MaterniT21™ Noninvasive Prenatal Test for Down Syndrome
Sequenom press release |  17 October 2011
7 December 2015 - by Antony Starza-Allen 
The US federal court of appeals has declined to rehear arguments on the patentability of a prenatal blood test, saying that it remains bound by the Supreme Court to determine the claims as non-patentable...
22 June 2015 - by Ceri Durham 
A US federal appeals court has upheld a ruling that Sequenom's prenatal MaterniT21 test is not sufficiently 'inventive' to be patentable....
22 July 2013 - by Dr Lucy Freem 
A method that 'switches off' entire chromosomes has been used in isolated cells to target the genetic defect behind Down's syndrome...
10 June 2013 - by James Brooks 
A test using only a blood sample taken from a pregnant woman is more reliable than current checks in indicating the likelihood of Down's syndrome, say researchers...
7 May 2013 - by James Brooks 
I know what they say about yesterday's news and today's fish and chip paper but what I'm about to tell you is six months old and still a little way off as a headline...
17 January 2011 - by Owen Clark 
New research suggests that Down's syndrome could be detected using genetic screening, avoiding the need for invasive detection procedures....
6 September 2010 - by Chris Chatterton 
Researchers from Newcastle University have announced that they have a better understanding of 'why older women are more likely to produce abnormal eggs, increasing the risk of infertility...
23 November 2009 - by Dr Will Fletcher 
A new drug that is being developed may lessen the effects of learning difficulties caused by the genetic condition Down's syndrome. Children with the condition are not developmentally delayed at birth, but often fall behind as they grow older because of memory deficits. A new study in mice, published in the journal Science Translational Medicine, has identified the key brain defects responsible and has pointed out a strategy for dealing with them through medication. The US resea...
1 September 2009 - by Ailsa Stevens 
BioNews reporting from the British Society for Human Genetics (BSHG) annual conference in Warwick:...
12 May 2009 - by Ben Jones 
The effectiveness of a prenatal test for Down syndrome has been thrown into doubt after its developers, Sequenom, admitted that study data had been 'mishandled' by its employees. The company, which had been producing apparently strong results in house for its DNA and RNA blood testing products...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.